# Public payers cover academic CAR-T at cost as a benchmark for commercial prices

Source: https://onco.cc/ideas/idea-reg-academic-cart-at-cost-coverage/  
OnCo record `idea-reg-academic-cart-at-cost-coverage` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hospitals in Spain make their own CAR-T for a third of the commercial price. Paying for such products at cost gives health systems a lever in negotiating with companies.

## Summary

ARI-0001 and similar academic products are reimbursed in Spain under the hospital exemption at a fraction of commercial list prices, and published outcomes are comparable in matched populations. The proposal is for other public payers to establish explicit coverage of academic point-of-care CAR-T at audited cost plus a fixed margin, publish that cost, and use it as the reference price in negotiations for commercial products in the same indication, creating a competitive benchmark that does not otherwise exist for single-source therapies.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Payers that cover academic CAR-T at cost negotiate commercial CAR-T prices at least 25% lower than payers without an academic alternative within three years, and treat more patients per unit spend.
- Rationale: Monopoly pricing persists where there is no alternative; a credible, reimbursed public-sector alternative is the fastest way to create one for cell therapies, since biosimilar-style competition does not yet exist.
- Proposed test: Compare commercial CAR-T net prices and patient volumes between Spain and comparable European countries; replicate by establishing academic coverage in one further country and remeasuring after three years.
- Maturity: early-clinical
- Actor: payer

## Sources

- Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017): https://doi.org/10.1038/nrclinonc.2017.31

## Connected records

- ideas: [Hospital-made CAR-T under one shared regulatory master file](https://onco.cc/ideas/idea-reg-point-of-care-cart-network/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [The high price of anticancer drugs: origins, implications, barriers, solutions](https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-academic-cart-at-cost-coverage.json